Author(s):

Vibeke Strand, Jennifer Sloane Lazar, Michael C Nivens, Jingdong Chao, Stefano Fiore, Angelika Giannelou, Lita Araujo, and Jerome Msihid

Abstract or description:

The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.

Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Years of Exposure

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Topics

Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

Safety Profile of a JAKi in Patients with Rheumatoid Arthritis With up to 6.5 Years of Exposure

Safety and Efficacy of a JAKi in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years From the SELECT-BEYOND Study

Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus

Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR

Do you get our email newsletter?